KLOTHO heterozygosity attenuates APOE4-related amyloid burden in preclinical AD.

Claire M Erickson Stephanie A Schultz Jennifer M OhBurcu F DarstYue MaDerek Norton Tobey J BetthauserCatherine L GallagherCynthia M CarlssonBarbara B BendlinSanjay AsthanaBruce P HermannMark A SagerKaj BlennowHenrik ZetterbergCorinne D EngelmanBradley T ChristianSterling C JohnsonDena B DubalOzioma C Okonkwo

Published in: Neurology (2019)

In a cohort of at-risk late-middle-aged adults, KL-VS heterozygosity was associated with an abatement of APOE4-associated Aβ aggregation, suggesting KL-VS heterozygosity confers protections against APOE4-linked pathways to disease onset in AD.

Keyphrases

cognitive decline
high fat diet
middle aged
adipose tissue
risk factors
metabolic syndrome
cell therapy
drug induced